Cargando…

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

Sequential application of target drugs is standard procedure after renal cell carcinoma (RCC) patients develop resistance. To optimize the sequence, antitumour effects of the mTOR inhibitor RAD001 or the tyrosine kinase inhibitor (TKI) sorafenib on RCC cells with acquired resistance to the TKI sunit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juengel, Eva, Kim, Dana, Makarević, Jasmina, Reiter, Michael, Tsaur, Igor, Bartsch, Georg, Haferkamp, Axel, Blaheta, Roman A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407590/ https://www.ncbi.nlm.nih.gov/pubmed/25444514 http://dx.doi.org/10.1111/jcmm.12471

Ejemplares similares

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells
por: Makarević, Jasmina, et al.
Publicado: (2014)

Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells
por: Tsaur, I, et al.
Publicado: (2012)

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
por: Juengel, Eva, et al.
Publicado: (2014)

Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2014)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells
por: Tsaur, Igor, et al.
Publicado: (2015)

I Publish in I Edit? - Do Editorial Board Members of Urologic Journals Preferentially Publish Their Own Scientific Work?
por: Mani, Jens, et al.
Publicado: (2013)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis
por: Wedel, Steffen, et al.
Publicado: (2011)

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro
por: Tsaur, Igor, et al.
Publicado: (2022)

Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro
por: Juengel, Eva, et al.
Publicado: (2016)

Publication of Original Research in Urologic Journals – A Neglected Orphan?
por: Mani, Jens, et al.
Publicado: (2012)

Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2019)

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
por: Tsaur, Igor, et al.
Publicado: (2015)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Juengel, Eva, et al.
Publicado: (2021)

HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
por: Makarević, Jasmina, et al.
Publicado: (2018)

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro
por: Juengel, Eva, et al.
Publicado: (2019)

Evaluation of TKTL1 as a biomarker in serum of prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2016)

Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
por: Markowitsch, Sascha D., et al.
Publicado: (2022)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
por: Juengel, Eva, et al.
Publicado: (2009)

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
por: Tsaur, Igor, et al.
Publicado: (2015)

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis
por: Markowitsch, Sascha D., et al.
Publicado: (2020)

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells
por: Tai, Sheng, et al.
Publicado: (2017)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020)

Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2016)

Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
por: Juengel, Eva, et al.
Publicado: (2017)

Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
por: Xie, Hui, et al.
Publicado: (2022)

Use of complementary and alternative medicine before and after organ removal due to urologic cancer
por: Mani, Jens, et al.
Publicado: (2015)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
por: Alshaker, Heba, et al.
Publicado: (2016)

Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro
por: Justin, Saira, et al.
Publicado: (2020)

Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation
por: Juengel, Eva, et al.
Publicado: (2023)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k2do02gmh9qdqbehma13eo2fcs